143 related articles for article (PubMed ID: 21756066)
1. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.
Camgoz A; Gencer EB; Ural AU; Avcu F; Baran Y
Leuk Lymphoma; 2011 Aug; 52(8):1574-84. PubMed ID: 21756066
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Gencer EB; Ural AU; Avcu F; Baran Y
Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells.
Kartal M; Saydam G; Sahin F; Baran Y
Nutr Cancer; 2011; 63(4):637-44. PubMed ID: 21500096
[TBL] [Abstract][Full Text] [Related]
4. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells.
Cakir Z; Saydam G; Sahin F; Baran Y
J Cancer Res Clin Oncol; 2011 Feb; 137(2):279-86. PubMed ID: 20401667
[TBL] [Abstract][Full Text] [Related]
5. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
Baran Y; Bielawski J; Gunduz U; Ogretmen B
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.
Camgoz A; Gencer EB; Ural AU; Baran Y
Leuk Lymphoma; 2013 Jun; 54(6):1279-87. PubMed ID: 23098068
[TBL] [Abstract][Full Text] [Related]
7. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Huang WC; Tsai CC; Chen CL; Chen TY; Chen YP; Lin YS; Lu PJ; Lin CM; Wang SH; Tsao CW; Wang CY; Cheng YL; Hsieh CY; Tseng PC; Lin CF
FASEB J; 2011 Oct; 25(10):3661-73. PubMed ID: 21705667
[TBL] [Abstract][Full Text] [Related]
9. Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells.
Bassoy EY; Baran Y
Biomed Pharmacother; 2012 Mar; 66(2):103-10. PubMed ID: 22326625
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
Ekiz HA; Can G; Gunduz U; Baran Y
Hematology; 2010 Feb; 15(1):33-8. PubMed ID: 20132660
[TBL] [Abstract][Full Text] [Related]
11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
12. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
Nica AF; Tsao CC; Watt JC; Jiffar T; Kurinna S; Jurasz P; Konopleva M; Andreeff M; Radomski MW; Ruvolo PP
Cell Cycle; 2008 Nov; 7(21):3362-70. PubMed ID: 18948750
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
Salas A; Ponnusamy S; Senkal CE; Meyers-Needham M; Selvam SP; Saddoughi SA; Apohan E; Sentelle RD; Smith C; Gault CR; Obeid LM; El-Shewy HM; Oaks J; Santhanam R; Marcucci G; Baran Y; Mahajan S; Fernandes D; Stuart R; Perrotti D; Ogretmen B
Blood; 2011 Jun; 117(22):5941-52. PubMed ID: 21527515
[TBL] [Abstract][Full Text] [Related]
14. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
[TBL] [Abstract][Full Text] [Related]
15. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
[TBL] [Abstract][Full Text] [Related]
16. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
17. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
18. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Ito F; Miura M; Fujioka Y; Abumiya M; Kobayashi T; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N
Int J Hematol; 2021 Jan; 113(1):100-105. PubMed ID: 33025461
[TBL] [Abstract][Full Text] [Related]
19. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
20. Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects.
Peixoto-da-Silva J; Calgarotto AK; Rocha KR; Palmeira-Dos-Santos C; Smaili SS; Pereira GJS; Pericole FV; da Silva S Duarte A; Saad STO; Bincoletto C
Biomed Pharmacother; 2018 Mar; 99():237-244. PubMed ID: 29334667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
